MetaCap

Kodiak Sciences Inc (KOD)

NASDAQ: KODHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

97.17-0.73 (-0.75%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

KOD stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$4.08
52-week range
20.38 – 112.79
Day range
96.53 – 100.89
Volume / Avg
692.96K / 1.77M
Beta
—

52-week range

$20.38$112.79

KOD stock today

Shares of Kodiak Sciences (KOD) finished lower on Nov 20 at $97.17, a drop of 0.75% or $0.73 per share, versus the S&P 500's 3.70% decline. Trading was light, with 692.96K shares changing hands, about 39% of the average daily volume. At this level, KOD sits near the top of its 52-week range of $20.38 to $112.79: 13.8% below the high, set on Nov 13, 2026 and 376.8% above the low.

KOD is up 247.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 367.8%. Kodiak Sciences has posted a net loss over the last twelve months (EPS of -$4.08), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Kodiak Sciences

Company profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Victor Perlroth M.D.
Headquarters
Palo Alto, CA
Employees
144
IPO year
2018
Website
kodiak.com

Financial highlights

Full financials

Kodiak Sciences reported a net loss of $230.0 million, compared with a loss of $176.2 million a year earlier. Diluted earnings per share came in at -$4.32.

Kodiak Sciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-229.97M$-176.21M$-260.49M$-333.82M$-266.99M
EPS (diluted)$-4.32$-3.35$-4.97$-6.39$-5.16

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$129.50+33.27%

  • Strong buy 1
  • Buy 5
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $103.00High $150.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-1.05 vs $1.00
Surprise
-205.00%

KOD news

All KOD news

Kodiak Sciences peers

Health Care sector
KOD peer companies
CompanyPrice% ChgMarket capCompare
IBRXImmunityBio Inc.6.02-8.37%$6.40Bvs KOD
IMVTImmunovant Inc.31.77-2.31%$6.57Bvs KOD
SRRKScholar Rock Holding Corporation48.13-4.45%$5.87Bvs KOD
TWSTTwist Bioscience Corporation103.32-7.44%$7.04Bvs KOD
CGONCG Oncology Inc.79.47-2.97%$7.10Bvs KOD
ADPTAdaptive Biotechnologies Corporation27.93-0.43%$4.52Bvs KOD
PCVXVaxcyte Inc.55.39-5.09%$8.77Bvs KOD
CRSPCRISPR Therapeutics AG39.10+0.44%$3.79Bvs KOD

Indexes, lists and sector

Kodiak Sciences stock FAQ

What is Kodiak Sciences's stock price today?

KOD last traded at $97.17 as of Nov 20, 4:00 PM EST, down 0.75% on the day. Prices are delayed at least 15 minutes.

Who is Kodiak Sciences's CEO?

Dr. Victor Perlroth M.D. is the chief executive officer of Kodiak Sciences Inc, which has about 144 employees.

What is the KOD 52-week high?

The 52-week high for KOD is $112.79 and the 52-week low is $20.38. The stock is currently 13.8% below its high.

Compare KOD